Serotonin decreases the duration of action potentials recorded from tetraethylammonium-treated bullfrog dorsal root ganglion cells.
Neurotransmitter effects on calcium currents activated by sensory neuron action potentials have been previously studied in embryonic or neonatal dorsal root ganglion (DRG) cells in culture. In the present study we examined the effects of serotonin (5-HT) on the shape of action potentials recorded from fully differentiated primary afferent neurons in isolated DRG of adult bullfrogs. Intracellular recordings were obtained from cell bodies of type A and C neurons. Concentrations of 5-HT that had no effect on membrane potential or input resistance had little or no effect on action potential shape. Treatment with 5-20 mM tetraethylammonium ion (TEA) led to the appearance of a plateau phase on the falling limb of the spike. This plateau phase appears to result from calcium influx, as it was dramatically reduced in amplitude and duration by solutions containing low concentrations of calcium or the calcium channel blocker, manganese. In preparations treated with 7.5 mM TEA, low concentrations of 5-HT (10 nM-1 microM) produced a dose-dependent narrowing of the calcium-dependent plateau phase of the mixed sodium/calcium spike. A decrease in spike afterhyperpolarization was also noted. The decrease in spike duration was recorded from 74% of type A neurons and 57% of type C neurons, and was not secondary to a change in resting potential or input resistance. The 5-HT receptor antagonists methysergide and metergoline did not block the response to 5-HT. Instead, they exhibited weak agonist-like actions. Serotonin also reduced the rate of rise and peak amplitude of calcium spikes recorded in the presence of tetrodotoxin and TEA.(ABSTRACT TRUNCATED AT 250 WORDS)
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D005727:Ganglia, Spinal / Q000187:drug effects* / Q000502:physiology; D008274:Magnesium / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D009412:Nerve Fibers / Q000187:drug effects; D009413:Nerve Fibers, Myelinated / Q000187:drug effects; D009475:Neurons, Afferent / Q000187:drug effects / Q000502:physiology; D011892:Rana catesbeiana; D012701:Serotonin / Q000494:pharmacology*; D013757:Tetraethylammonium Compounds / Q000494:pharmacology*; D013779:Tetrodotoxin / Q000494:pharmacology
D013757:Tetraethylammonium Compounds; D012701:Serotonin; D013779:Tetrodotoxin; D008274:Magnesium; D002118:Calcium; D008784:Methysergide